Phase 2, Nab Paclitaxel/Gemcitabine Alone and in Combination With ACP-196 in Subjects With Metastatic Pancreatic Cancer
Status:
Terminated
Trial end date:
2016-04-01
Target enrollment:
Participant gender:
Summary
To evaluate the safety and efficacy of ACP-196 and nab paclitaxel/gemcitabine in subjects
with previously untreated metastatic pancreatic cancer using standard response criteria